|
Advertisement |
|
|
||
 |
|
|||||
|
|||||
|
 |
||||||
|
||||||
|
||||||
|
Originally published as JCO Early Release 10.1200/JCO.2009.23.0045 on July 13 2009 © 2009 American Society of Clinical Oncology.
Genetic Basis of Bilateral Renal Cancer: Implications for Evaluation and ManagementUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD Kidney cancer is estimated to affect more than 54,000 individuals in the United States each year and to be responsible for 13,000 deaths in the United States annually.1 When a patient with localized kidney cancer is treated surgically, 5- and 10-year disease-specific survival can approach 95%. However, despite the remarkable recent advances in targeted therapeutics for kidney cancer, this disease is still fatal for the majority of patients who present with advanced disease. In this issue of Journal of Clinical Oncology, Wiklund et al2 report an elegant study of the risk of bilateral kidney cancer. In this population-based study from Norway and Sweden, the authors defined the risk of development of bilateral kidney cancer in 28,642 patients observed for an average of 4.4 years. They found asynchronous renal cell cancer in 86 patients. One hundred twelve metachronous bilateral kidney cancer cases were detected during 126,493 person years of follow-up, revealing an overall relative risk of 3.1, with a cumulative incidence of 0.85 after 20 or more years of follow-up. A striking observation in the current work was the finding of a significant increase in relative risk of bilateral disease for young patients diagnosed with this kidney cancer. When compared with the general population, Wiklund et al found a 90% increase in risk for contralateral disease when a patient 60 years or older was diagnosed with kidney cancer, whereas in patients younger than 40 years of age, there was an 1,800% increased risk for the development of cancer in the remaining kidney.2 This article raises a number of important issues in the evaluation and management of patients with kidney cancer. Does bilateral disease represent metastasis of the cancer from one kidney to the other, or does it result from a genetic predisposition? In some patients with widespread metastatic disease, metastases may account for tumors in the contralateral kidney. However, in the great majority of patients, the multiple/bilateral tumors seem to arise independently, as occurs in a number of the inherited forms of kidney cancer, such as von Hippel-Lindau (VHL) and Birt-Hogg-Dubé syndrome (Table 1).3,4 It is also likely that in most instances of nonfamilial bilateral, multifocal kidney cancer, the tumors arise independently. Wiklund et al2 report on the incidence of bilateral kidney cancer; however, because of the magnitude and nature of this large study, the authors were not able to categorize the tumors by histologic type or to assess the prevalence of multifocality within an individual kidney. If a tumor is bilateral, it is, by definition, multifocal. The nature of this large study likely underestimates the true incidence of bilateral kidney cancer (given that the surveillance was limited to 4 years) and it is likely that in many of the patients there was occult intrarenal multifocality. The finding of bilateral tumors in such a large percentage of patients with this disease suggests that these patients have a genetic predisposition to develop renal cell cancer, and that a single gene alteration is responsible for the development of each of the tumors. This raises the possibility that many patients carry a hereditary predisposition to develop kidney tumors, and their management should be based on the expectation that additional kidney tumors may develop in these patients. If so, removing the entire kidney may be suboptimal, because much of the remaining kidney at the time of surgery may be disease free and functional, and it may be needed in the future.
It has been estimated that 5% to 10% of renal cancers are hereditary. However, 5% to 10% is most likely a significant underestimate of the true hereditary predisposition to renal cancer Important insight into this question comes from the study of Gudbjartsson et al,5 who studied all patients in Iceland who had renal cancer from 1955 to 1999. When Gudbjartsson et al evaluated whether these individuals with kidney cancer had a relative with kidney cancer, they found a much higher risk in first-degree relatives as well as a significantly higher risk for renal cancer in members of the extended family of an affected individual.5 The Icelandic study suggests that there may be a genetic predisposition in nearly 60% of patients with kidney cancer. The results from the current study of Wiklund et al2 suggest that young patients with kidney cancer should be actively monitored for the development of recurrence of cancer in the ipsi- or contralateral kidney, and that the possibility of hereditary kidney cancer should be considered. The results demonstrating an increased incidence of both synchronous and metachronous bilateral kidney tumors will influence current thinking on the management of this disease. The increased incidence of bilateral kidney tumors provides an additional rationale for the use of partial nephrectomy in the management of patients with localized kidney cancer. If a patient were at increased risk of the development of another cancer in the contralateral kidney, the patient would often be better served by a nephron-sparing approach to therapy of the first kidney cancer. In addition, these results highlight the need to carefully evaluate and monitor the patient with localized kidney cancer for bilateral as well as multifocal disease. The finding that there is a 17-fold higher risk for the development of bilateral kidney cancer in patients younger than age 40 years reinforces the need to search for a genetic cause of kidney cancer in patients with bilateral disease, particularly among those younger than 40 years. An important key to the evaluation and management of patients with bilateral or multifocal kidney cancer lies in the renal cancer pathology. Kidney cancer is not a single disease; it is made up of a number of different types of cancer that occur in the kidney.6–8 The pathology of the kidney tumor, the patient's clinical phenotype, as well as family history guide the physician to the subsequent evaluation and management of the patient. The first familial renal cancer gene identified was discovered in families with VHL.9 There are now seven recognized familial renal cancer syndromes, each has a characteristic pathology, associated physical findings, and mutations in a specific gene that were discovered in extensive family studies. Patients with VHL are at risk for the development of tumors in a number of organs, including the kidney.10–12 A family history of retinal angioma, cerebellar or spinal hemangioblastoma, pancreatic neuroendocrine tumors, or pheochromocytomas strongly suggests VHL. In this instance, germline mutation testing for the VHL gene is recommended. Patients affected with hereditary papillary renal carcinoma (HPRC) are at risk for the development of bilateral, multifocal type 1 papillary kidney cancer.13,14 HPRC is caused by germline mutation of the MET gene.15,16 Birt-Hogg-Dubé (BHD) patients are at risk for the development of bilateral, multifocal chromophobe, and hybrid-oncocytic renal tumors as well as benign cutaneous tumors, fibrofolliculomas,17 pulmonary cysts, and recurrent pneumothorax.18 BHD is characterized by germline mutation of the BHD gene.19,20 In patients at risk for BHD, germline mutation testing for the BHD gene is recommended. Similar to VHL and HPRC, BHD-associated renal tumors are often managed expectantly until the largest tumor reaches approximately 3 cm in size.21 Familial renal oncocytoma (FRO) is another familial syndrome in which affected individuals are at risk for the development of bilateral, multifocal oncocytoma.22 FRO is often confused with BHD; however, patients with FRO do not have pulmonary cysts or fibrofolliculoma, and do not have germline mutation of the BHD gene. The renal tumors in patients with FRO are benign and managed expectantly. Patients affected with tuberous sclerosis (TSC) are at risk for manifestations in a number of organs, including the development of bilateral renal tumors, cutaneous lesions, CNS hamartomas, and pulmonary cysts.23,24 The characteristic TSC renal tumor is a benign angiomyolipoma, although patients with TSC have also been found to have clear cell, chromophobe, and papillary renal tumors. Hereditary leiomyomatosis renal cell carcinoma (HLRCC) is another hereditary renal cancer syndrome in which affected individuals are at risk for the development of bilateral kidney tumors and cysts as well as cutaneous and uterine leiomyomas.25 HLRCC is characterized by germline mutation of the Krebs cycle enzyme, fumarate hydratase.26,27 HLRCC-associated renal tumors are different from VHL, HPRC, or BHD kidney tumors. HLRCC-associated kidney tumors have a pathologic phenotype suggestive of type 2 papillary or collecting duct renal carcinoma, and are aggressive tumors that tend to spread to lymph nodes and can metastasize when the primary tumor is small (< 1 cm).28,29 Familial pheochromocytoma/paraganglioma (PGL) is another hereditary kidney cancer syndrome in which affected individuals are at risk for the development bilateral and extra-adrenal pheochromocytoma or neck paraganglioma.30–32 PGL is characterized by germline mutation of one of the B, C, or D isoforms of another Krebs cycle enzyme, succinate dehydrogenase (SDHB, SDHC, or SDHD). Recently, early-onset, bilateral, multifocal kidney cancer has been detected in families with SDHB PGL.32–35 SDHB and fumarate hydratase germline mutation testing should be considered in patients with early-onset renal cancer, such as many of those described by Wiklund et al.2 Although Wiklund et al2 were not able to ascertain histologic subtypes in this study, clinical management of patients with bilateral, multifocal renal cancer depends on the histologic type of the renal tumors as well as the patient's clinical phenotype and the family history. It is highly likely that many of the bilateral kidney cancers identified by Wiklund et al occur in individuals who have an underlying genetic abnormality, particularly in early-onset disease. Management of these patients is greatly improved by identifying the genetic cause of the disease. Understanding the genetic basis of bilateral, multifocal renal cancer and the characteristics of the hereditary types of renal cancer provides the foundation for rational evaluation and management of patients who develop kidney cancer. AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The author(s) indicated no potential conflicts of interest. Acknowledgment This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. The author thanks Tracey A. Rouault, MD, for thoughtful suggestions, and Georgia Shaw for editorial support. REFERENCES
1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71–96, 2008. 2. Wiklund F, Tretli S, Choueiri TK, et al: Risk of bilateral renal cell cancer. J Clin Oncol 27:3737–3741, 2009. 3. Walther MM, Lubensky IA, Venzon D, et al: Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: Clinical implications. J Urol 154:2010–2014, 1995.[CrossRef][Medline] 4. Vocke CD, Yang Y, Pavlovich CP, et al: High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst 97:931–935, 2005. 5. Gudbjartsson T, Jonasdottir TJ, Thoroddsen A, et al: A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer 100:476–479, 2002.[CrossRef][Medline] 6. Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol 170:2163–2172, 2003.[CrossRef][Medline] 7. Linehan WM, Zbar B: Focus on kidney cancer. Cancer Cell 6:223–228, 2004.[CrossRef][Medline] 8. Linehan WM, Pinto PA, Srinivasan R, et al: Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13:671s–679s, 2007. 9. Latif F, Tory K, Gnarra JR, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320, 1993. 10. Linehan WM, Lerman MI, Zbar B: Identification of the VHL gene: Its role in renal carcinoma. JAMA 273:564–570, 1995. 11. Lonser RR, Glenn GM, Walther MM, et al: von Hippel-Lindau disease. Lancet 361:2059–2067, 2003.[CrossRef][Medline] 12. Butman JA, Linehan WM, Lonser RR: Neurologic manifestations of von Hippel-Lindau disease. JAMA 300:1334–1342, 2008. 13. Zbar B, Tory K, Merino MJ, et al: Hereditary papillary renal cell carcinoma. J Urol 151:561–566, 1994.[Medline] 14. Zbar B, Glenn GM, Lubensky IA, et al: Hereditary papillary renal cell carcinoma: Clinical studies in 10 families. J Urol 153:907–912, 1995.[CrossRef][Medline] 15. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73, 1997.[CrossRef][Medline] 16. Schmidt L, Junker K, Weirich G, et al: Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58:1719–1722, 1998. 17. Birt AR, Hogg GR, Dube WJ: Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 113:1674–1677, 1977. 18. Zbar B, Alvord WG, Glenn GM, et al: Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 11:393–400, 2002. 19. Nickerson ML, Warren MB, Toro JR, et al: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2:157–164, 2002.[CrossRef][Medline] 20. Schmidt LS, Nickerson ML, Warren MB, et al: Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 76:1023–1033, 2005.[CrossRef][Medline] 21. Pavlovich CP, Grubb RL, Hurley K, et al: Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 173:1482–1486, 2005.[CrossRef][Medline] 22. Weirich G, Glenn GM, Junker K, et al: Familial renal oncocytoma: Clinicopathological study of 5 families. J Urol 160:335–340, 1998.[CrossRef][Medline] 23. Cheadle JP, Reeve MP, Sampson JR, et al: Molecular genetic advances in tuberous sclerosis. Hum Genet 107:97–114, 2000.[CrossRef][Medline] 24. Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med 355:1345–1356, 2006. 25. Launonen V, Vierimaa O, Kiuru M, et al: Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 98:3387–3392, 2001. 26. Tomlinson IP, Alam NA, Rowan AJ, et al: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406–410, 2002.[CrossRef][Medline] 27. Toro JR, Nickerson ML, Wei MH, et al: Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 73:95–106, 2003.[CrossRef][Medline] 28. Grubb RL III, Franks ME, Toro J, et al: Hereditary leiomyomatosis and renal cell cancer: A syndrome associated with an aggressive form of inherited renal cancer. J Urol 177:2074–2080, 2007.[CrossRef][Medline] 29. Merino MJ, Torres-Cabala C, Pinto P, et al: The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31:1578–1585, 2007.[Medline] 30. Baysal BE, Ferrell RE, Willett-Brozick JE, et al: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848–851, 2000. 31. Baysal BE: Clinical and molecular progress in hereditary paraganglioma. J Med Genet 45:689–694, 2008. 32. Neumann HP, Pawlu C, Peczkowska M, et al: Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943–951, 2004. 33. Vanharanta S, Buchta M, McWhinney SR, et al: Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 74:153–159, 2004.[CrossRef][Medline] 34. Ricketts C, Woodward ER, Killick P, et al: Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 100:1260–1262, 2008. 35. Henderson A, Douglas F, Perros P, et al: SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Fam Cancer doi: 10.1007/s10689-009-9234-2.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||
|
|||||||||||
|
|
Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|
